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Aims To examine the impact of COVID-19 on acute heart failure (AHF) hospitalization rates, clinical characteristics and
management of patients admitted to a tertiary Heart Failure Unit in London during the peak of the pandemic.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Methods
and results
Data from King’s College Hospital, London, reported to the National Heart Failure Audit for England and Wales,
between 2 March–19 April 2020 were compared both to a pre-COVID cohort and the corresponding time periods
in 2017 to 2019 with respect to absolute hospitalization rates. Furthermore, we performed detailed comparison of
patients hospitalized during the COVID-19 pandemic and patients presenting in the same period in 2019 with respect
to clinical characteristics and management during the index admission. A significantly lower admission rate for AHF
was observed during the study period compared to all other included time periods. Patients admitted during the
COVID-19 pandemic had higher rates of New York Heart Association III or IV symptoms (96% vs. 77%, P = 0.03)
and severe peripheral oedema (39% vs. 14%, P = 0.01). We did not observe any differences in inpatient management,
including place of care and pharmacological management of heart failure with reduced ejection fraction.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Conclusion Incident AHF hospitalization significantly declined in our centre during the COVID-19 pandemic, but hospitalized
patients had more severe symptoms at admission. Further studies are needed to investigate whether the incidence
of AHF declined or patients did not present to hospital while the national lockdown and social distancing restrictions
were in place. From a public health perspective, it is imperative to ascertain whether this will be associated with
worse long-term outcomes.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Keywords Acute heart failure • COVID-19 • Coronavirus • Hospitalization • Management •
National Heart Failure Audit
Introduction
Acute heart failure (AHF) is a life-threatening condition that
typically mandates admission to hospital, urgent investigation and
treatment. In England and Wales, AHF was cited as the primary
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.. diagnosis for more than 90 000 admissions in 2017 to 2018 and
was associated with in-hospital mortality of 10.1%.1 Furthermore,
among patients surviving to discharge, 1-year mortality was 32%.1
There are several, well-established factors associated with 1-year
post-discharge mortality, broadly grouped into three categories:
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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patient characteristics reflecting the severity of heart failure (HF)
[e.g. age, New York Heart Association (NYHA) class, left ventricu-
lar function], hospitalization factors [including specialist cardiology
input, initiation of therapy for HF with reduced ejection fraction
(HFrEF) and length of stay] and follow-up arrangements.1 It has
been shown repeatedly that 1-year mortality is lower for patients
admitted to cardiology wards compared to general medical wards,
as well as for those receiving specialist multi-disciplinary HF man-
agement and receiving optimal medical therapy for HFrEF during
the admission.1,2
The COVID-19 pandemic is a global public health emergency.
The high burden on healthcare systems, including the National
Health Service (NHS) in England and Wales, has mandated rapid
redirection of services to manage the influx of patients with
COVID-19. This is especially true in London, which has experi-
enced the highest burden of COVID-19 in the UK. This transfor-
mation has included cessation of routine treatment and face-to-face
follow-up of many conditions to both reduce the risk of infec-
tion to at-risk groups and create extra capacity of both personnel
and beds. Furthermore, there has been a concurrent decline in
patients presenting with many acute medical conditions, includ-
ing acute coronary syndromes (ACS).3,4 To date, little is known
about whether similar trends are apparent in AHF, or whether
the patient, hospitalization and follow-up factors that predict out-
comes have changed during the current crisis. It is also not
known if COVID-19 has contributed to an increase in AHF admis-
sions, as respiratory illness is well known to contribute to HF
decompensation.5
Therefore, the present study compared patients presenting with
AHF to a tertiary Heart Failure Unit in a London teaching hospital
in March–April 2020 to the same period in 2019. We aimed
to compare these cohorts with respect to factors associated
with outcome, described above, including absolute hospitalization
rates, patient characteristics and management during the index
admission. We hypothesized that the incidence of hospitalization
for AHF would decline during the COVID-19 pandemic and that
inpatient management and follow-up arrangements would be worse
during the pandemic compared to the corresponding period in
2019.
Methods
Study design and population
The numbers of consecutive patients hospitalized for AHF in King’s
College Hospital between 2 March 2020, the date of the first coron-
avirus death in England, and 19 April were compared to hospitalization
numbers over the same number of weeks before the study period and
corresponding time periods in 2017 to 2019. Next, we performed
detailed comparison of patients hospitalized during the COVID-19
pandemic and patients presenting in the same period in 2019. Finally,
we examined hospital admissions with a diagnosis of HF in the sec-
ond position, comparing the study period to the same period in 2019,
to ascertain whether patients were admitted with AHF secondary to
COVID-19.
The Heart Failure Unit at this hospital provides comprehensive



















































































.. including: an electronic referral service to allow daily review of all
admissions to hospital with HF by a consultant cardiologist (irre-
spective of their place of admission), nurse education for inpatients,
advice regarding optimal medical therapy and facilitation of follow-up
post discharge. This service operated normally during the pandemic
period. All patients are admitted to the hospital via the emer-
gency department. Patients <18 years of age were excluded from the
analysis.
Variables were extracted from local National Heart Failure Audit
(NHFA) data. The NHFA collects data relating to AHF hospitaliza-
tions from NHS Trusts in England and Health Boards in Wales. Patients
were entered into the audit if they had a primary discharge diag-
nosis of AHF, based on appropriate ICD codes [I11.0 Hypertensive
heart disease with (congestive) heart failure; I25.5 Ischaemic cardiomy-
opathy; I42.0 Dilated cardiomyopathy; I42.9 Cardiomyopathy, unspec-
ified; I50.0 Congestive heart failure; I50.1 Left ventricular failure;
I50.9 Heart failure, unspecified], and these data were interrogated for
the study.
Data fields
Mandatory fields in the NHFA were collected, including demographics,
presenting symptoms and signs, comorbidities, diagnostic tests, place
of care, specialist input, length of stay, prescribing for HFrEF and
in-hospital mortality. The standard dataset used for the NHFA is avail-
able from NICOR (https://www.nicor.org.uk/national-cardiac-audit-
programme/datasets).
Primary and secondary outcomes
The primary outcome was the rate of hospitalization for AHF. Sec-
ondary outcomes were place of care, rates of specialist input, discharge
medication for HFrEF and in-hospital mortality.
Statistical analyses
Demographic and baseline characteristics of the study populations
were compared using the Pearson Chi-square test for categorical
variables, Student’s t-test (parametric) or Mann–Whitney U test
(non-parametric) for continuous variables, or one-way ANOVA for
multiple comparisons. Normality of distribution was assessed by the
Shapiro–Wilks test. Continuous variables were reported as means
(standard deviation) or median [interquartile range (IQR)], as appropri-
ate. Categorical variables were reported as numbers (percentage). Inci-
dence rates for the primary outcome (HF hospitalizations per 100 000
people per week) were calculated by dividing the number of cumula-
tive events per week by the catchment population of King’s College
Hospital. Incidence rate ratios comparing the exposed (2020) to the
unexposed (2019) period were calculated using Poisson regression to
model the number of HF hospitalizations per week. A quadratic term
was used to fit hospitalization trends in both the exposed and unex-
posed cohorts and compared by means of the extra-sum-of-square
F test. Gaussian fitting was employed to plot the daily number of
COVID-19 cases. All analyses were conducted using SPSS statistics
software, version 20.0 (IBM Corp., Armonk, NY, USA), Stata software,
version 13.1 (StataCorp., College Station, TX, USA) and ‘R’ (R Project
for Statistical Computing).
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Weekly admissions for heart failure pre- and post-COVID-19 and in corresponding time periods in 2017 to 2019.
Figure 2 Numbers and trends of heart failure hospitalization by year. CI, confidence interval; IRR, incidence rate ratio.
Results
During the study period, we identified 26 patients hospitalized
in King’s College Hospital with AHF as the primary diagnosis,
which was significantly lower than the number of admissions in the
pre-COVID period, or any of the years 2017 to 2019 (Figure 1).
Furthermore, the relative risk of hospitalization decreased over
time compared to the corresponding time period in 2019 (Figure 2).
No patients with a primary diagnosis of AHF also had a diagnosis
of COVID-19.
Patient baseline characteristics according to exposure group
are shown in Table 1. Patients had similar mean age at AHF
admission (73±14 years in 2020 vs. 71± 15 years in 2019), similar




















. vs. 39%). Overall, comorbidities and cardiovascular risk factors
were similar between patients presenting in each year (Table 1),
although fewer patients in 2020 had pre-existing, significant valve
disease (27% vs. 51%, P = 0.04). Furthermore, similar proportions
presented with decompensated HFrEF (69% vs. 63%) and HF with
preserved ejection fraction (31% vs. 37%) and this is consistent
with overall NHFA data.1
We observed that patients hospitalized in 2020 had a higher
proportion with NYHA class III or IV symptoms (96% vs. 77%,
P = 0.03) and severe peripheral oedema (39% vs. 14%, P = 0.01;
Table 1).
In-hospital management of patients was similar in our centre
in 2019 and 2020. Fewer patients were admitted to cardiology
wards (23% vs. 37%) or reviewed by HF specialists (56% vs. 78%)
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Baseline characteristics by year of presentation
2019 (n = 78, 75%) 2020 (n = 26, 25%) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age (years), mean (SD) 71 (15) 73 (14) NS
Male sex, n (%) 45 (58) 14 (54) NS
Height (cm), mean (SD) 167 (9) 167 (9) NS
Race, n (%) NS
White 41 (53) 14 (54)
Black 30 (39) 11 (42)
Other 7 (9) 1 (4)
Admission BMI (kg/m2), mean (SD) 30 (9) 31 (8) NS
Admission heart rate (bpm), mean (SD) 88 (24) 86 (25) NS
Admission rhythm, n (%)
Sinus rhythm 41 (54) 10 (42) NS
Atrial fibrillation 29 (38) 12 (50) NS
Admission blood pressure (mmHg), mean (SD)
Systolic 134 (26) 140 (30) NS
Diastolic 79 (17) 78 (21) NS
NYHA class, n (%) 0.01
I 4 (5) 0 (0)
II 14 (18) 1 (4)
III 41 (53) 10 (38)
IV 19 (24) 15 (58)
Severity of oedema, n (%) 0.02
None 10 (13) 5 (19)
Mild 19 (24) 5 (19)
Moderate 38 (49) 6 (23)
Severe 11 (14) 10 (39)
HF classification at admission, n (%)
HFrEF 48 (63) 18 (69) NS
HFpEF 28 (37) 8 (31)
Comorbidities, n (%)
Ischaemic heart disease 29 (37) 8 (31) NS
Acute myocardial infarction 8 (10) 5 (19) NS
Valve disease 40 (51) 7 (27) 0.04
Hypertension 54 (69) 21 (81) NS
Diabetes 39 (50) 14 (54) NS
Asthma 7 (9) 2 (8) NS
COPD 16 (21) 5 (19) NS
Device 13 (17) 9 (35) NS
BMI, body mass index; COPD, chronic obstructive pulmonary disease; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced
ejection fraction; NYHA, New York Heart Association; SD, standard deviation.
in 2020 compared to 2019, but these findings were not significant
(Table 2). Moreover, length of stay [6 (IQR 4–9) days in 2020
vs. 7 (IQR 3–13) days in 2019] and multi-disciplinary HF team
follow-up (31% in 2020 vs. 28% in 2019) were unchanged between
the two cohorts. We did not observe any differences in discharge
medication between 2019 and 2020, with similar proportions
being discharged on evidence-based therapy for HFrEF (Table 3).
Furthermore, we observed no difference in discharge daily diuretic
dose (119± 83 mg in 2020 vs. 108± 77 mg in 2019, P = 0.55).
In-hospital mortality was very low in both years, which precluded
statistical comparison. Our inpatient mortality rates have been
significantly lower than the NHFA average for the last 8 years.
Finally, one patient had COVID-19 as a primary diagnosis and




















. hospitalized with HF as the secondary diagnosis during the study
period, which was significantly lower than the 52 seen in 2019
(P = 0.004; Figure 3).
Discussion
While the impact of the COVID-19 pandemic on ACS has been
reported,3,4 little is known about its effects on the admission
and management of patients with AHF. We report a significant
decline in hospitalization rates for AHF during the COVID-19
pandemic, compared to before the pandemic and each of the
preceding 3 years. Compared to the same period in 2019, the
relative risk of hospitalization for AHF progressively reduced during
the COVID-19 pandemic. The same was true for HF diagnoses in
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 In-hospital management by year of presentation
2019 (n = 78, 75%) 2020 (n = 26, 25%) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Place of care, n (%) NS
Cardiology 29 (37) 6 (23)
General medicine 40 (51) 19 (73)
Other 9 (12) 1 (4)
Specialist input, n (%) 61 (78) 15 (56) NS
Discharge bloods, mean (SD)
Haemoglobin (g/L) 119 (22) 115 (17) NS
Urea (mmol/L) 11 (8) 12 (7) NS
Creatinine (μmol/L) 130 (83) 144 (66) NS
Sodium (mmol/L) 138 (4) 139 (3) NS
Potassium (mmol/L) 4.2 (0.6) 4.3 (0.5) NS
Weight change (kg), mean (SD) −3 (3) −3 (4) NS
Length of stay (days), median [IQR] 7 [3–13] 6 [4–9] NS
Multidisciplinary HF team follow-up 22 (28) 8 (31) NS
Died in hospital, n (%) 2 (2) 1 (4) NS
HF, heart failure; IQR, interquartile range; SD, standard deviation.
Table 3 Discharge medication for patients with heart failure with reduced ejection fraction by year of presentation
Discharge medication 2019 (n = 48, 73%) 2020 (n = 18, 27%) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ACEI or ARB 37 (77) 15 (83) NS
Beta-blocker 43 (90) 14 (78) NS
Diuretic 45 (94) 17 (94) NS
MRAs 27 (56) 10 (56) NS
ACEI or ARB, beta-blocker and MRA 20 (42) 7 (39) NS
Digoxin 10 (21) 3 (18) NS
Values are given as n (%).
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; MRA, mineralocorticoid receptor antagonist.
Figure 3 Numbers and trends of heart failure diagnoses in the second diagnostic position by year.
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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the second position and only one patient had a co-existing diagnosis
of COVID-19, despite the known increase of COVID-19 among
patients with cardiovascular comorbidity.6 It is unknown if the
incidence of AHF has declined or if our findings reflect a reluctance
to attend hospital, although similar reports on ACS suggest the
latter.4
We observed a higher proportion of black patients than are
reported in most AHF cohorts, which reflects our local popula-
tion (for example, a study using Clinical Practice Research Datalink
reported 96.1% of incident HF cases to be among Caucasians7).
Compared to 2019, patients were, in general, more unwell with
higher rates of NYHA class III or IV symptoms and severe periph-
eral oedema, which are known predictors of poor outcomes in
AHF.8,9 Following admission, in-hospital management was simi-
lar between the two cohorts. We did not observe a difference
in discharge daily diuretic dose, although this may not reflect
in-hospital treatment. Similarly, we observed no significant dif-
ference in rates of specialty input, main place of care, length
of stay or pharmacological management of HFrEF. This reflects
the fact that we continued to provide our comprehensive inpa-
tient care model during the pandemic. However, despite this, our
early experience suggests a trend towards more patients being
managed on general medical wards and fewer receiving specialist
HF input.
Taken together, our data might suggest that patients with less
severe AHF have avoided presenting to hospital, although we
were unable to confirm this in our study. The national lockdown
and social distancing restrictions may have reduced respiratory
tract infections, which are a common trigger for HF decom-
pensation. However, it is unlikely that this would account for a
decline only in patients with milder symptoms. While there is no
evidence for the outcome of patients with decompensated HF
managed in the community, it is expected that this will trans-
late to a subsequent increase in HF hospitalization and mortality.
This is likely to be exacerbated by the known decline in ACS
presentations during this period that will no doubt lead to an
increase in the prevalence and incidence of HF in the months
to come.
Based on these findings, it is imperative to carefully examine
longitudinal primary care, hospitalization and mortality data for HF
to ascertain the reasons for, and implications of, the shift towards
fewer, sicker patients being hospitalized for AHF.10 It is likely that
such analyses, including comparison of different models of care
during the COVID-19 pandemic, can help inform our response to
future public health emergencies.
Strengths and limitations
The NHFA is a well established registry that sets the performance
standards for hospitals as to what constitutes optimal HF care, as
well as being the mechanism for remuneration of hospitals achiev-
ing the key performance indicators with the Best Practice Tariff
(for submission of at least 70% of primary admissions with HF
to the audit and making sure that 60% of those receive specialist
care during the admission). Furthermore, as a single-centre study,



















































































.. However, this work has the usual limitations of observational data,
including potential bias as a result of unmeasured residual con-
founding, and the fact that observed differences may be due to
unmeasured variables. Moreover, the results may not be generaliz-
able to other Heart Failure Units. We can only report associations
with year of presentation, rather than causal relationships, and
patients presenting at different times may differ with respect to
unrecorded variables.
Conclusion
We report a decline in AHF hospitalization in our centre dur-
ing the COVID-19 pandemic, but hospitalized patients had more
severe symptoms. Further studies are needed to investigate
whether the incidence of AHF truly declined or patients did
not present to hospital while the lockdown and social distanc-
ing restrictions were in place. From a public health perspective,
it is imperative to ascertain whether this is associated with worse
outcomes.
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